KARPAGA VINAYAGA INSTITUTE OF MEDICAL SCIENCES AND

KARPAGA VINAYAGA INSTITUTE OF MEDICAL SCIENCES AND RESEARCH CENTRE

GST Road, Chinnakolambakkam, Madhuranthagam, Tamilnadu -603308

Ph.no: 044-71565100;Fax: 044-27565170;E-mail: [email protected], [email protected]; Website: www.kims.edu.in

CBME TIME TABLE (PHASE II) BATCH: 2019-20 15.03.2021 TO

31.12.2021

DAY

&

DAT

E

8.30AM TO

9.30AM

9.3

0A

M

TO

12.

30

PM

12.

30

P

M

TO

1.0

0

P

M

1.00 PM TO 2.00PM

2.00PM

TO

3.30PM

3.30PM

TO

4.30PM

15/03

/2021

MON

PH. 1.1:

Introduction to

Pharmacology &

Pharmacotherapeu

tics (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH (SGT)- PA 1.1-

Department orientation

PATH

(SGT)- 2.3,

2.5

Intracellula

r

accumulati

ons,

Pathologic

calcificatio

n

16/03

/2021

TUE

PATH(L) PA 1.1-

1.3 Introduction to

Pathology

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.9 Nomenclature

of drugs (SGT)

PH 1.9 General Introduction for practical session & Drug nomenclatures (Practical)

17/03

/2021

WED

PATH(L) PA 2.1,

2.2 Cell injury-

Mechanisms

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MI 1.2 Microscopy

lecture

(Practicals)

MI 1.2

Microscopy

PATH

(SGT)-

PA 2.6

Cellular

adaptati

ons

18/03

/2021

THU

R

Microbiology

(Lecture)

MI

1.1Introduction

and History.

CL

INI

CA

L

PO

STI

LU

NC

H

PH 1.3 Enumerate drug

delivery systems &

route of drug

administration (L)

FM 1.1,1.2

:

Introductio

n & history

of FM -

Lecture,




NG

S

SGD

19/03

/2021

FRI

PH. 1.4

Pharmacokinetics:

Absorption,

Distribution of

Drugs(L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

Microbiology(Lecture)

MI 1.4 Sterilization and

Disinfection

Microbiolo

gy(SGD)

MI 1.4 &

1.5

Sterilizatio

n

20/03

/2021

SAT

IA (PHARM) IA

LU

NC

H

IA

AETCOM

2.1 Intro

session

22/03

/2021

MON

PH. 1.4

Pharmacokinetics:

Metabolism

(Biotransformatio

n) (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH (SGT)- PA 2.7

Cell Injury-Newer

forms of cell death &

Autophagy

PATH

(DOAP)-

PA 2.8 Cell

Injury-I

23/03

/2021

TUE

PATH(L) PA 2.4

Cell death-types,

mechanisms,

Necrosis and

Gangrene

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.4. ADME of

drugs (SGT)

PH 1.12

Calculate

dosage of

the drug

using

appropriate

formula for

individual

patient

including

children,

elderly &

patient with

Renal

dysfunction

(P)

24/03

/2021

WED

PATH(L) PA 2.7

Apoptosis and

Cellular aging

CL

INI

CA

L

PO

LU

NC

H

Microbiology SGD

MI 1.4 & 1.5

Disinfection

Microbiolo

gy(Practica

ls) MI

1.4 & 1.5

Sterilizatio

n and

PATH

(DOAP)

- PA 2.8

Cell

Injury-II




STI

NG

S

Disinfectio

n

(including

CSSD

Visit)

25/03

/2021

THU

R

Microbiology(Lec

ture) MI

1.1Overview of

bacterial

infections

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH. 1.4

Pharmacokinetics:

Excretion (L)

FM

1.3,1.4,1.6 :

Legal

procedures-

I Courts,

Court

procedures,

Offense -

Lecture,

SGD

26/03

/2021

FRI

PH 1.5 General

Principles of

Mechanism of

action (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H


MI 1.1 Bacterial

Taxonomy

Microbiolo

gy (SDL)

MI 1.1

Physiology

of Bacteria

27/03

/2021

SAT

AETCOM

MODULE 2.1

contd

IA

LU

NC

H

AETCOM 2.1

Foundations of

communication 2

AETCOM

2.1 contd

29.03

.2021

Mon

PH 1.7 Define,

identify &

Describe

managemen of

ADR (L)

LU

NC

H

PATH (SGT)- PA 4.4-

Acute inflammation-

Morphology, Outcomes

& systemic effects

PATH

(DOAP)-

PA 4.4-

Acute

Inflammati

on

30.03

.2021

Tues

PATH(L) PA 4.1-

Inflammation

general

features,vascular

and cellular events

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.8 Management of

Drug Interaction (P)

PH 1.12

Dosage

calculation

for

individual

patient

including

children,

elderly &

patient with

Renal

dysfunction




(P) II

31.03

.2021

Wed

PATH(L)Vertical

integration with

Surgery- PA 4.2-

Mediators of acute

Inflammation

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY

SGD MI 1.1 Methods

of gene transfer

MICROBI

OLOGY

(PRACTIC

AL)

MI

1.2Gram

staining 1

PATH

(DOAP)

- PA

4.4-

Chronic

Inflamm

ation

01.04

.2021

Thurs

Microbiology

(Lecture)

MI 1.1

Morphology of

Bacteria B

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.16

Antihistaminics (L)

FM 1.5 to

1.8 : Legal

procedure-

II - mock

court

02.04

.2021

Fri

PH 1.16 5HT

Drug Modulators

& Drugs therapy

for Migraine (

INT) medicine (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

Microbiology

(Lecture) M1 1.1

Bacterial genetics

Microbiolo

gy (SGD)

M1 1.1

Culture

media &

Methods

03.04

.2021

Sat

IA MICRO IA

LU

NC

H

AETCOM

2.2Foundation of

Bioethics (2 hrs)

AETCOM

2.2

05.04

.2021

Mon

PH 1.16 NSAID

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH (SGT)- PA 3.1-

Amyloidosis

PATH

(DOAP)-

PA 3.2-

Amyloidosi

s-I

06.04

.2021

Tues

PATH(L) PA 4.3

Chronic

Inflammation

CL

INI

CA

LU

NC

H

PH 1.16 Prostaglandins

(SGT)

1.6:

Principles

of

Pharmacovi




L

PO

STI

NG

S

gilance &

ADR

reporting

system

(Practical)

07.04

.2021

Wed

PATH(L)Vertical

Integration with

Surgery- PA 5.1

Repair &

Regeneration-I

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY

Microbiology(SGD)

MI 8.9 Specimen

collection & transport -

I

MICROBI

OLOGY(Pr

acticals)

M1.1.Cultu

re media &

methods

PATH

(DOAP)

- PA

3.2-

Amyloid

osis-II

08.04

.2021

Thurs

Microbiology

(Lecture)M 1.6

Antimicrobial

agents & AMR

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.13 ANS

introduction (L)

FM 2.1 to

2.4 :

Integration

with

PATH-

Death & its

causes -

Lecture,

SGD

09.04

.2021

Fri

PH 1.14

Cholinergic

transmission &

cholinergics (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H


M1.6 Antimicrobial

susceptibility testing

Microbiolo

gy(SGD)

MI 8.9

Specimen

collection

& transport

-II

10.04

.2021

Sat

IA (PHARM) IA

LU

NC

H

AETCOM 2.3 Health

care as a Right AETCOM

12.04

.2021

Mon

PH 1.14 MOA,

Doses, side

effects,

Indications of

anti-cholinergics

/Antimucarinics

(L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SGT) PA 5.1

Repair & Regeneration-

II

PATH(SG

T-Vertical

Integration

with GM)

PA 6.1-

Edema




13.04

.2021

Tues

PATH(L) Vertical

Integration with

Surgery- PA 6.3-

Shock

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.11 Describe

various routes of drug

administration (

IM/IV/SC/SL/oral)

SGT

PH 4.1

Administer

drug

through

various

route in

simulated

environmen

t ( DOAP)

14.04

.2021

Wed

Holid

ay

CL

INI

CA

L

PO

ST

IN

GS

LU

NC

H

15.04

.2021

Thurs

Microbiology(Lec

ture) MI 1.1

Antimicrobial

stewardshio

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.13 Adrenergics

(L)

FM 2.5 to

2.7 :

Integration

with

PSYCHIA

TRY &

PATH

Death & its

causes -

LECTURE,

SGD

16.04

.2021

Fri

PH 1.13

Antiadrenergics

(L) Alpha

Blockers

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H


M1.1 Overview of viral

infections infections 1

Microbiolo

gy(SGD)

M1.1

Identificati

on of

Bacteria

(Convetion

al methods)

17.04

.2021

Sat

IA (PATH) IA

LU

NC

H

IA AETCOM

19.04

.2021

Mon

PH 1.13 Anti

adrenergics Beta

Blockers (L)

CL

INI

CA

L

LU

NC

H

PATH(SGT) PA 6.2-

Hyperemia, Congestion

and Hemorrhage

PATH(SG

T) PA 6.6-

Ischemia &

Infarction




PO

STI

NG

S

20.04

.2021

Tues

PATH(L) PA 6.4-

Thrombosis

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.14 Glaucoma :

INT Physiology of

aqueous formation,

Drugs used in

glaucoma-pharm,

Symptoms & Surgical

Rx of glaucoma. (SGT)

PH 1.10

Describe

correct,

complete &

legible

parts of

prescription

identify

errors in

prescription

(P) I

21.04

.2021

Wed

PATH(L) PA 6.5-

Embolism

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

Microbiology SGD

M1.1 Laboratory

diagnosisi of Viral

infection - Molecular

Microbiolo

gy(Practica

l) M1.1

Laboratory

diagnosisi

of Viral

infection -

Microscopy

,

Cultivation,

Serology &

Molecular

PATH(

DOAP)

PA 6.7-

Infarctio

n &

CVC

22.04

.2021

Thurs

Microbiology

(Lecture)M1.1

Overview of viral

infections

infections &

General virology

11

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.16 5HT Drug

Modulators & Drugs

therapy for Migraine (

INT) medicine (L)

FM 1.9 :

Death

certificate -

LECTURE,

SGD

23.04

.2021

Fri

PH1.62

Antispetics &

Disinfectants (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

Microbiology (Lecture)

M1.1 Overview of

Parsitic infections 1

Microbiolo

gy(SGD)

M1.1

Identificati

on of

Bacteria

(Automatio

n &

Molecular




methods)

24.04

.2021

Sat

2.4 AETCOM 6

hrs IA

LU

NC

H

Working in a Health

care team

AETCOM

2.4

26.04

.2021

Mon

PH 1.17 Local

Anaesthetics (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SGT) Vertical

Integration with

Surgery- PA 8.1, 8.2-

Basic Diagnostic

Cytology

PATH(DO

AP) PA

8.3-

Diagnostic

cytology-

FNAC

27.04

.2021

Tue

PATH(L) PA 7.1-

Neoplasia General

features

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 3.7 Prepare a list of

Essential medicine for

healthcare facility

(SGT) Practical I

PH 1.10

Describe

correct,

complete &

legible

parts of

prescription

identify

errors in

prescription

(P) II

28.04

.2021

Wed

PATH(L) PA 7.2-

Molecular basis of

Cancer

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

Microbiology lecture

MI 1.1 lab diagnosis

of parasitic infections

Microbiolo

gy

(Practicals)

MI 1.1

Stool

Microscopy

&

peripheral

blood

smear

PATH(

DOAP)

PA 8.3-

Diagnost

ic

cytology

-LBC,

Pap

smear

29.04

.2021

Thur

Microbiology(Lec

ture) MI 1.1

Laboratory

diagnosis of

Fungal infections

& General

Mycology

CL

INI

CA

L

PO

STI

NG

LU

NC

H

PH 1.49 Anticancer (L)

FM 2.8,2.9

: PM

changes-I -

LECTURE,

SGD,

DOAP




S

30.04

.2021

Fri

PH 1.18 General

Anaesthesthetics

(L) -Int.

Anaesthesia

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H


MI 1.1 Microbial

pathogenesisi 1

Microbiolo

gy(SGD)

MI 1.1

Normal

Microbial

flora of

human

body

01.05

.2021

Sat

Holid

ay

MAY DAY

M

AY

DA

Y

M

AY

DA

Y

MAY DAY MAY DAY MAY

DAY

03.05

.2021

Mon

PH 1.19

Antidepressant (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SGT) PA 7.4-

Paraneoplastic

syndrome & Clinical

effects of neoplasia

PATH(DO

AP) PA

7.1-

Common

benign and

malignant

tumors

04.05

.2021

Tue

PATH(L) PA 7.3-

Carcinogenesis I

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.59: Essential

Medicine, FDC, OTC

drugs and herbal

medicine (SGT)

PH 1.10

Describe

correct,

complete &

legible

parts of

prescription

identify

errors in

prescription

(P) III

05.05

.2021

Wed

PATH(L) PA 7.3-

Carcinogenesis II

& Lab diagnosis

CL

INI

CA

L

PO

STI

NG

LU

NC

H

Microbiology lecture

MI.1, 1.2 Laboratory

diagnosis of fungal

infections

Microbiolo

gy(Practica

ls) MI.1,

1.2

Laboratory

diagnosis

of fungal

infection :

PATH(S

GT) PA

7.5-

Immune

response

to

cancer




S KOH

mount ,

Gram

stain(Yeast

), India ink

& LPCB

06.05

.2021

Thur

Microbiology

(Lecture) MI 1.1

Microbial

pathogenesisi 11

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.19 Sedative

hypnotics (L)

FM 2.10 :

PM

changes-II -

LECTURE,

SGD,

DOAP,AU

TOPSY

Pandemi

c

Module

:2.1

Infection

Control:

Part II

Air

borne

precauti

ons 3.30

pm –

5.30 pm(

Microbi

ology)-

2 hours

07.05

.2021

Fri

PH 1.19 Anti

psychotics (L)

Psychiatry ( INT)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

Microbiology(Lectture)

MI 1.3 Epidemiology

of Infectious diseases

Microbiolo

gy (SGD)

MI 1.1

Microbial

pathogenesi

s

Pandemi

c

Module

:2.1

Infection

Control:

Part II

Air

borne

precauti

ons 3.30

pm –

5.30 pm(

Microbi

ology)-

2 hours

08.05

.2021

Sat

IA (FM)

2.5

(6

hrs)

AE

TC

O

M

LU

NC

H

2.5 Bioethics continued

(case studies on patient

autonomy & decision

making ) AETCOM

AETCOM




10.05

.2021

Mon

PH 1.19 Anti

epileptics (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(Seminar) PA

12.2-Nutritional

disorders

PATH(SG

T) PA 12.3-

Obesity

11.05

.2021

Tue

PATH(L) Vertical

Integration with

GM-PA 21.1 to

PA 21.3- Normal

hemostasis;

Platelet disorders,

Hemophilia,

VWD

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.20 Ethyl &

methyl achohol,

Alchohol addiction

(SGT)

PH 3.2

Perform

and

interrupt a

critical

appraisal

(Audit) of a

given

prescription

I

12.05

.2021

Wed

Holid

ay

HOLIDAY

HO

LI

DA

Y

H

OL

ID

AY

13.05

.2021

Thur

Microbiology(Lec

tture) MI 1.7

Immmunity

(Innate &

Acquired)-

Immunological

mechanism of

health

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.19 Drugs for

Parkinsonism ( Int)

Medicine case of

Parkinsonism (L)

FM

2.20,2.21 :

Mechanical

Asphyxia-I

-

LECTURE,

SGD,

DOAP,

AUTOPSY

Pandemi

c

Module

: 2.2

Emergin

g and

Re-

emergin

g

infection

s, early

identific

ation

and

control

of new

infection

s 3.30

pm –

5.00 pm(

Commu




nity

medicin

e )- 1 hr

30 mins

14.05

.2021

Frida

y

PH 1.19 Anti

epileptics II(L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

Microbiology(Integrate

d) MI 1.3

Epidemiological bacis

of commom infectious

diseases

Microbiolo

gy(Integrat

ed) MI 1.9

Immunolog

ical basis of

vaccines

and

describe the

universal

immunisati

on schedule

Pandemi

c

Module

: 2.2

Emergin

g and

Re-

emergin

g

infection

s, early

identific

ation

and

control

of new

infection

s 3.30

pm –

5.00 pm(

Commu

nity

medicin

e )- 1 hr

30 mins

15.05

.2021

Sat

IA (PHARM) IA

LU

NC

H

2.6 (2.5hrs) Bioethics

continued AETCOM

2.6 (2.5hrs)

Bioethics

continued

AETCOM

17.05

.2021

Mon

PH 1.19 Opioid

analgesics (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SGT) PA 23.1-

Urine examination

PATH(DO

AP) PA

23.1-Urine

examinatio

n




18.05

.2021

Tue

PATH(L) PA

21.4, PA 21.5-

DIC, Vitamin-K

deficiency

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.19 Antimanic

drugs (SGT)

PH 3.2

Perform

and

interrupt a

critical

appraisal

(Audit) of a

given

prescription

II

19.05

.2021

Wed

PATH(L) PA 21.3

to PA 21.5-

Approach to

bleeding disorders

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY

SDL MI 6.6 structure

and functions of

immune system

MICROBI

OLOGY

(PRACTIC

AL)

MI 1.2Acid

fast

staining- 1

PATH(S

eminar)

PA 12.1-

Environ

mental

disorder

s

20.05

.2021

Thur

Microbiology(Lec

ture) MI 1.8

Organs of Immune

system

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.25 Coagulants &

Anticoagulants (L)

FM 2.22 :

Mechanical

Asphyxia-

II -

LECTURE,

SGD,

DOAP

Pandemi

c

Module

: 2.2

Emergin

g and

Re-

emergin

g

infection

s, early

identific

ation

and

control

of new

infection

s 3.30

pm –

5.00 pm(

Commu

nity

medicin

e )- 1 hr

30 mins




21.05

.2021

Fri

PH 1.25

Antiplatelets (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

Microbiology( Lecture)

MI 1.8 Cells of

Immune system

Microbiolo

gy (SDL)

MI 1.8

Antigen

Pandemi

c

Module

: 2.2

Emergin

g and

Re-

emergin

g

infection

s, early

identific

ation

and

control

of new

infection

s 3.30

pm –

5.00 pm(

Commu

nity

medicin

e )- 1 hr

30 mins

22.05

.2021

Sat

IA (PATH) IA

LU

NC

H


continued AETCOM

2.6 (2.5hrs)

Bioethics

continued

AETCOM

24.05

.2021

Mon

PH 1.25

Fibrinolytics &

Antifibrinolytics

(L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH (SGT)PA 23.2

Body fluid analysis

PATH(DO

AP) PA

35.3-CSF

analysis

interpretati

on

25.05

.2021

Tue

PATH(L) PA

28.15- Thrombotic

microangiopathies

CL

INI

CA

L

PO

STI

LU

NC

H

PH 3.7 Prepare a list of

Essential medicine for

healthcare facility II

(SGT)

PH 3.2

Perform

and

interrupt a

critical

appraisal

(Audit) of a

Pandemi

c

Module

: 2.5

Sample

Collecti

on,




NG

S

given

prescription

III

Microbi

al

diagnosi

s,

Serologi

c tests

and their

perform

ance

paramet

ers 3.30

pm –

5.00 pm(

Microbi

ology )-

1 hr 30

mins

26.05

.2021

Wed

PATH(L) Clinical

path Vertical

Integration with

GM-PA 32.2, PA

32.3

Hypothyroidism

and

Thyrotoxicosis

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY

MI6.3

Immunoglobulins SDL

MICROBI

OLOGY

(PRACTIC

AL)

MI 1.2Acid

fast

staining- 2

PATH(

DOAP)

PA 23.3-

Semen

analysis,

RFT

interpret

ation

27.05

.2021

Thur

Microbiology(Lec

ture) MI 1.8

Antibody

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.15 skeletal muscle

relaxant - MOA,Types,

Side Effects,

Indications,

Contraindications (L)

FMT 2.23 :

Mechanical

ASphyxia-

III

Drowning -

LECTURE,

SGD,

DOAP,AU

TOPSY

Pandemi

c

Module

: 2.5

Sample

Collecti

on,

Microbi

al

diagnosi

s,

Serologi

c tests

and their

perform

ance

paramet

ers 3.30

pm –




5.00 pm(

Microbi

ology )-

1 hr 30

mins

28.05

.2021

Fri

PH 1.50

Immunomodulator

s (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H


MI 1.8 Antigen

antibody reaction 1

Microbiolo

gy

(Lecture)

MI 1.8

Antigen

antibody

reaction 11

Pandemi

c

Module

: 2.5

Sample

Collecti

on,

Microbi

al

diagnosi

s,

Serologi

c tests

and their

perform

ance

paramet

ers 3.30

pm –

5.00 pm(

Microbi

ology )-

1 hr 30

mins

29.05

.2021

Sat

IA (MICRO) IA

LU

NC

H


continued AETCOM

2.7 (2.5hrs)

Bioethics

continued

AETCOM

31.05

.2021

Mon

PH 1.42 Principles

of Chemotherapy

(L) INT Micro

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH (SGT) PA 23.3

TFT, LFT

interpretation

PATH

(DOAP)

PA 23.3

TFT, LFT

interpretati

on-Charts

Pandemi

c

Module

: 2.5

Sample

Collecti

on,

Microbi

al

diagnosi

s,

Serologi




c tests

and their

perform

ance

paramet

ers 3.30

pm –

5.00 pm(

Microbi

ology )-

1 hr 30

mins

01.06

.2021

Tue

PATH(L)Clinical

path Vertical

Integrationwith

Surgery- PA 25.1

Jaundice

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.48

Sulphonamides (SGT)

PH 1.3

Enumerate

& identify

drug

formulation

s &

delivery

systems I

Drug

delivery in

GA & LA

02.06

.2021

Wed

PATH(L) PA 9.1-

Principles and

mechanisms of

immunity-I

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY

Lecture MI 1.8 &

8.15 Antigen Antibody

reactins II

MICROBI

OLOGY

(PRACTIC

AL)

MI 1.8 &

8.15

Antigen

Antibody

reactins(Co

nventional)

-

Agglutinati

on &

precipitatio

n

PATH(S

GT) PA

9.1-

Principle

s and

mechani

sms of

immunit

y-II

03.06

.2021

Thur

MICROBIOLOG

Y (LECTURE)

MI

1.8Complement

CL

INI

CA

L

PO

STI

LU

NC

H

PH 1.43 Rational use of

antibiotics INT with

Micro and Paeds (L)

FM 3.1,

14.4 :

Identificati

on -I -

LECTURE,

SGD,

DOAP,BE




NG

S

DSIDE

CLINIC

04.06

.2021

Fri

PH 1.48

Fluroquinolones

(L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY

(LECTURE)

MI 1.8 Immune

responses:CMI

MICROBI

OLOGY

(SGD)

MI 1.8

Immune

responses:

CM

05.06

.2021

Sat

IA (FM) IA

LU

NC

H


continued AETCOM

2.7 (2.5hrs)

Bioethics

continued

AETCOM

07.06

.2021

Mon

PH 1.48 Beta

lactum antibiotics

I (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SGT)

H.Integration with

Micro- PA 9.2, MI 1.10

Hypersensitivity

Reactions

PATH(SG

T) PA 9.2-

Hypersensit

ivity

Reactions

II

08.06

.2021

Tue

PATH(L) PA 9.4

Autoimmunity

Mechansim and

Immunological

tolerance

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.48 Beta lactum

antibiotics II (SGT)

PH 1.3

Enumerate

& identify

drug

formulation

s &

delivery

systems I

Inhaler,

Nebulizer,

Rotahaler

09.06

.2021

Wed

PATH(L) Vertical

Integration with

GM-PA 9.5-

Autoimmune

disorders & SLE

CL

INI

CA

L

PO

STI

NG

LU

NC

H

MICROBIOLOGY

Lecture MI 1.8 &

8.15 Antigen Antibody

reactins III

MICROBI

OLOGY

(PRACTIC

AL)

MI 1.8 &

8.15

Antigen

Antibody

PATH(S

GT) PA

9.7-

Other

Autoim

mune

disorder

s




S reactins(Ne

wer) -

ELISA,

ELFA,

CLIA,

IFA,Wester

nblot,

Rapid

methods

10.06

.2021

Thur

Microbiology

(Lecture) MI 1.10

Autoimmunity

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.48 Macrolides (L)

FM 3.1 :

Integration

with

Anatomy

Identificati

on-

II(religion,

complexion

) -

LECTURE,

SGD,

DOAP

11.06

.2021

Fri

PH 1.48

Tetracylcine &

Chlormphenicol

(L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY MI 1.10 (SGT)

Lab diagnosis of immunological

disorder

12.06

.2021

Sat

IA (PHARM) IA

LU

NC

H

2.8 AETCOM What

does it mean to be a

family member of a

sick patient ? 1

2.8

AETCOM

What does

it mean to

be a family

member of

a sick

patient ?

14.06

.2021

Mon

PH 1.46 Drugs in

Leprosy (INT)

Micro- diagnosis

of leprosy,

Dermat: Clinical

signs &

Complicaions in

CL

INI

CA

L

PO

STI

NG

LU

NC

H

PATH(SGT) PA 10.2,

10.4- Common

infections

PATH(SG

T)H.Integra

tion with

Micro- PA

10.3-

Leprosy




Leprosy (L) S

15.06

.2021

Tue

PATH(L) H.

Integration with

Micro MI 2.7 -PA

9.6-

Immunodeficiency

& AIDS I

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.48

Aminoglycosides

(SGT)

PH 3.8

Communic

ate

effectively

with a

patient on

proper use

of

prescribed

medication.

(P)

16.06

.2021

Wed

PATH(L) PA 9.6-

AIDS II

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H


MI 1.9

Immunohematology

MICROBI

OLOGY

(PRACTIC

AL)

MI 1.2

Stool

Microscopy

PATH(S

GT) PA

9.6-

Primary

Immuno

deficien

cy

17.06

.2021

Thur

Micro L MI 2.7

HIV 2

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.48 Anti viral

agents (L)

FM 3.1 :

Integration

with

Anatomy

Identificati

on- III

Osteology,

Odontology

, X ray -

LECTURE,

SGD,

DOAP

18.06

.2021

Fri

PH 1.48 Anti

retro-viral agents

(L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

Microbiology MI 1.11 (Integrated) -

Transplant & Cancer immunology




19.06

.2021

Sat

IA (PATH) IA

LU

NC

H

2.8 AETCOM What


family member of a

sick patient ? 2

2.8

AETCOM

What does

it mean to

be a family

member of

a sick

patient ? 2

21.06

.2021

Mon

PH 1.48

Antifungal agents

(L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SGT)H.

Integration with Micro-

PA 9.3-HLA system

and Transplant

rejection

PATH(SG

T) PA 9.3-

GVHD

22.06

.2021

Tue

PATH(L) Vertical

Integration with

GM, Surgery- PA

22.4-Blood

components

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 3.3 Perform Critical

evaluation of drug

promotional literature I

PH 1.3

Enumerate

& identify

drug

formulation

s &

delivery

systems I

Drug

delivery in

GA & LA

(P)

23.06

.2021

Wed

PATH(L) Vertical

Integration with

GM- PA 22.6-

Transfusion

reactions

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H


MI 8.5, 8.6 Basics of

infection control

MICROBI

OLOGY

(PRACTIC

AL)

MI

8.7Hand

hygiene

PATH(S

GT) PA

22.1,

PA22.2,

PA 16.7-

Blood

grouping

&

Compati

bility

testing

24.06

.2021

Thur

Microbiology

(Lecture) MI 1.9

Immunoprophlyax

is

CL

INI

CA

L

LU

NC

H

PH 1.47 Anti-

helminthic agents(L)

FM

3.2,14.9 :

Identificati

on-IV

(Superimpo




PO

STI

NG

S

sition) -

Lecture,SG

D,DOAP

25.06

.2021

Fri

PH 1.48 Anti

amoebic agnets

(L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H


MI 8.5, 8.6,8.7 Hospital

Acquired Infection

MICROBI

OLOGY

(SDL) MI

8.5, 8.6

Biomedical

waste

26.06

.2021

Sat

IA (MICRO) IA

LU

NC

H

2.8 AETCOM What


family member of a

sick patient ? 3

2.8

AETCOM

What does

it mean to

be a family

member of

a sick

patient ? 3

28.06

.2021

Mon

PH 1.53 Heavy

Metal Poisoning

& Chelating

agents (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SGT) Vertical

Integration with Paed-

PA 11.1-Common

cytogenetic

abnormalities in

childhood

PATH(SG

T) Vertical

Integration

with Paed-

PA 11.3-

Common

Storage

disorders

29.06

.2021

Tue

PATH(L) PA

13.1, 13.3, 13.4-

Hematopoiesis,

Classification &

Investigations of

Anemia including

PCV & ESR

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 2.4 Demonstrate

correct method of

calculation of drug

dosage in patients

including those use in

special situation I

neonate, Children &

Elderly (DOAP)

PH 2.4

Demonstrat

e correct

method of

calculation

of drug

dosage in

patients

including

those use in

special

situation II

Pregnacy,

Liver &

Kidney

Dysf.




(DOAP)

30.06

.2021

Wed

PATH(L) Vertical

Integration with

GM-PA 14.1,

14.2- Iron

metabolism &

Microcytic

hypochromic

anemia

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H


MI 8.8 Bacteriology of

Water food ,Milk and

Air

MICROBI

OLOGY

(PRACTIC

AL)

MI 8.7 PPE

PATH(S

GT) PA

11.2-

Tumor

and

Tumor-

like

conditio

ns in

childhoo

d

01.07

.2021

Thur

CM(SGT/INTG/TUTO)CM1.1 Define and describe the concept of Public Health (L) CM(L)&SDL Define health; describe the concept of holistic health including concept of spiritual health and the relativeness & determinants of health (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

FM 6.1,14.6 to 14.8 :

INTEG WITH PATH

& PHYSIOLOGY -

Blood stains, DNA

fingerprintingLecture,S

GD

FM

6.1,14.6 to

14.8 :

INTEG

WITH

PATH &

PHYSIOL

OGY -

Blood

stains,

DNA

fingerprinti

ngLecture,

SGD

02.07

.2021

Fri

MICROBIOLOG

Y (SDL) MI 8.5,

8.6 Needle stick

injury

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

CM(L)&(SDL) CM1.7 Enumerate and describe health indicators (SGD)




03.07

.2021

Sat

IA (PHARM) IA

LU

NC

H

OBGY(SGT/INTG/SL)

+B1243 OG

12.2Define, classify

and describe the

etiology,

pathophysiology,

diagnosis,

investigations, adverse

effects on the mother

and foetus

and the management

during pregnancy and

labor, and

complications of

anemia in pregnancy

SU6.1

Define and

describe the

aetiology

and

pathogenesi

s of

surgical

Infections

05.07

.2021

Mon

PATH(L) Vertical

Integration with

GM-PA 15.1,

15.2, 15.4-

Macrocytic

anemia

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SGT) PA 13.2-

Role of Anticoagulants

in hematology

PATH(DO

AP) PA

13.5, 14.3,

15.3, 16.6-

Peripheral

smear

identificati

on in

Anemias I

06.07

.2021

Tue

PH 1.35:

Hematinics (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 2.3 Demonstrate

appropriate setting of

IV drip in a stimulated

environment (P)

PH 2.3

Demonstrat

e

appropriate

setting of

IM in a

stimulated

environmen

t (P)

07.07

.2021

Wed

IM9.2 Describe

and discuss the

morphological

characteristics,

aetiology

and prevalence of

each of the causes

of anemia.

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY

(SGD) MI 2.4

Infections causing

anaemia

Practicals :

MI 1.3

Stool

examinatio

n

PATH(S

GT) PA

17.2-

Bone

marrow

aspiratio

n and

trephine

biopsy




08.07

.2021

Thur

CM(SGT/INTG/TUTO)CM1.6 Describe and discuss the concepts, the principles of Health promotion and Education, IEC and Behavioral change communication (BCC) (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

FM 6.2,6.3 : FSL -

Specimen encountered,

analysis & interp -

Lecture,SGD,

FM 7.1 :

Narcoanaly

sis & brain

mapping -

Lecture,SG

D

09.07

.2021

Fri

MICROBIOLOG

Y (Lecture)

MI 1.1Blood

stream infections,

sepsis, septic

shock, CRBSI

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

CM(L)&(SDL)CM1.9 Demonstrate the role of effective Communication skills in health in a simulated environment (DOAP sessions)

10.07

.2021

Sat

IA (PATH) IA

LU

NC

H

OBGY(L) OG 16.1

Enumerate and discuss

causes, prevention,

diagnosis,

management,

appropriate use of

blood and blood

products in

postpartum

haemorrhage

SU2.1

Describe

Pathophysi

ology of

shock,

types of

shock &

principles

of

resuscitatio

n including

fluid

replacemen

t and

monitoring.

12.07

.2021

Mon

PATH(L) PA

16.1, 16.2, 16.3-

Hemolytic

anemias-

Classification,

hematological

indices & Sickle

cell anemia

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SGT) PA 17.1-

Aplastic anemia &

other hypoproliferative

anemias

PATH(DO

AP) PA

13.5, 14.3,

15.3, 16.6-

Peripheral

smear

identificati

on in

Anemias II




13.07

.2021

Tue

PH 1.61 Dietary

supplements,

nutraceuticals and

miscellaneous

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.25 Seminar -

Blood

Ph 2.2

Prepare

Oral

rehydration

solution

from ORS

packet and

describe its

use (P)

14.07

.2021

Wed

IM1.3 Describe

and discuss the

aetiology

microbiology

pathogenies and

clinical evolution

of rheumatic

fever, criteria,

degree of

rheumatic

activity and

rheumatic valvular

heart disease and

its complications

including infective

endocarditis.

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY

SGD

MI 2.3, 8.15 1.1 Sepsis

CRBSI

MICROBI

OLOGY

(Practicals)

MI 2.3,

8.15 1.1

Sepsis

CRBSI,

Rheumatic

fever,

Infective

endocarditi

s

PATH(S

GT) PA

16.3 to

16.5-

Thalasse

mia and

other

Hemolyt

ic

anemias

15.07

.2021

Thur

CM(SGT/INTG/TUTO)CM1.8 Describe the Demographic profile of India and discuss its impact on health (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

FM 8.1 to 8.6 :

Integration with

Pharmacology - Gen

Toxicology -

Lecture,SGD,DOAP,A

utopsy

FM 8.1 to

8.6 :

Integration

with

Pharmacolo

gy - Gen

Toxicology

-

Lecture,SG

D,DOAP,A

utopsy

16.07

.2021

Fri

MICROBIOLOG

Y (LECTURE)

MI 2.1,

2.2Infections of

CVS (in detail)-

Rheumatic fever

and Infective

endocarditis

(including

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

CM(SGT/INTG/TUTO)CM1.8 Describe the Demographic profile of India and discuss its impact on health. Demography indicators and Fertility related statistics (SGD)




HACEK group)

17.07

.2021

Sat

IA (MICRO) IA

LU

NC

H

OBGY(SGT/INTG/SL)

OG 1.1, OG 1.2 Define and discuss birth rate,

maternal mortality and

morbidity, perinatal

mortality and morbidity including

perinatal and neonatal

mortality and morbidity audit

SU26.1

Outline the

role of

surgery in

the

manageme

nt of

coronary

heart

disease,

valvular

heart

diseases

and

congenital

heart

diseases

19.07

.2021

Mon

PATH(L)

Integration with

Micro & GM-PA

27.4, 27.6-

Rheumatic fever

and Infective

endocarditis

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SGT) Vertical

Integration with GM-

PA 27.1-

Atherosclerosis

PATH(SG

T) PA 27.2,

27.10-

Aneurysm

& Syphilis

CVS

manifestati

ons

20.07

.2021

Tue

Holid

ay

HOLIDAY




21.07

.2021

Wed

IM2.1 Discuss and

describe the

epidemiology,

antecedents and

risk

factors for

atherosclerosis

and ischemic heart

disease.

IM2.4 Discuss and

describe the

pathogenesis

natural history,

evolution

and complications

of atherosclerosis

and IHD

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY

lecture MI 3.3

salmonella MI 3.4,

8.15

Brucellosis,Leptospiros

is

MICROBI

OLOGY

(PRACTIC

AL)

MI 13.3 MI

13.4 MI

1.2 lab

diagnosis

of enteric

fever

PATH(S

GT)

Vertical

Integrati

on with

GM-PA

27.7-

Pericardi

tis and

Pericardi

al

effusion

22.07

.2021

Thur

CM(L)&(SDL)CM 2.2 Describe the socio-cultural factors, family (types), its role in health and disease (L) CM(L)&(SDL)CM2.5 Describe poverty and social security measures and its relationship to health and disease (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

FM 8.7,8.8 : INTEG

WITH PHARM & GM

Gen Toxicology -

Lecture,SGD,DOAP,Be

dside clinic

FM 8.7,8.8

: INTEG

WITH

PHARM &

GM Gen

Toxicology

-

Lecture,SG

D,DOAP,B

edside

clinic

23.07

.2021

Fri

MICROBIOLOG

Y(LECTURE)

MI 3.1Normal

commensals

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

CM(L)&(SDL)CM 2.2 Demonstrate in a simulated environment the correct assessment of socio-economic status (DOAP sessions) CM(L)&(SDL) CM 2.3 Describe and demonstrate in a simulated environment the assessment of barriers to good health and health seeking behavior (DOAP sessions)




24.07

.2021

Sat

IA (PHARM) IA

LU

NC

H

OBGY(L) OG 12.4

Define, classify and

describe the etiology,

pathophysiology,

diagnosis,

investigations, criteria,

adverse effects on the

mother and foetus and

the management during

pregnancy and labor,

and

complications of heart

diseases in pregnancy

SU14.1

Describe

Aseptic

techniques,

sterilization

and

disinfection

.

26.07

.2021

Mon

PATH(L) Vertical

Integration with

GM-PA 27.5-

Ischemic Heart

Disease

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SGT) Vertical

Integration with GM-

PA 27.9-

Cardiomyopathies

PATH(DO

AP) PA

27.8-

Interpretati

on of

Cardiac

function

tests

27.07

.2021

Tue

PH. 1.26 Drugs

Modulating

RAAS (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 3.3 Perform Critical

evaluation of drug

promotional literature I

PH 3.3

Perform

Critical

evaluation

of drug

promotiona

l literature

II

28.07

.2021

Wed

IM2.5 Define the

various acute

coronary

syndromes and

describe their

evolution, natural

history and

outcomes

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY

(SGD) MI 8.1

Brucelosis,

Leptospirosis

MICROBI

OLOGY

practicals

MI 8.1

Brucelosis,

Leptospiros

is &

Borreliosis

PATH(S

GT)

V.Integr

ation

with

GM,

Physio

PA 27.3-

Heart

failure

29.07

.2021

Thur

CM(SGT/INTG/TUTO) CM2.4 Describe social psychology, community behaviour and

CL

INI

CA

L

LU

NC

H

FM 8.9 : Maintainence

of records -

Lecture,SGD

FM 9.4 :

Alcohol I

Classificati

on-

ethanol,met




community relationship and their impact on health and disease (L)

PO

STI

NG

S

hanol,

Ethylene

glycol

Lecture,SG

D,DOAP,B

edside

clinic

30.07

.2021

Fri

MICROBIOLOG

Y(SDL) MI 1.1

Plague

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H CM(SGT/INTG/TUTO)CM1.10 Demonstrate the important aspects of the doctor patient relationship in a simulated environment (DOAP sessions)

31.07

.2021

Sat

IA(PATH) IA

LU

NC

H

OG 8.1 Enumerate,

describe and discuss the

objectives of antenatal

care, assessment of

period of gestation;

screening for high-risk

factors.

SU28.11

Describe

the applied

anatomy of

spleen.

Describe

the clinical

features,

investigatio

ns and

principles

of

manageme

nt of

splenic

injuries.

Describe

the post-

splenectom

y sepsis -

prophylaxis

02.08

.2021

Mon

PATH(SGT) PA

18.1- Benign

Leukocyte

disorders

CL

INI

CA

L

PO

STI

NG

LU

NC

H

PATH(SGT) PA 18.2 -

Acute leukemias

PATH(SG

T) PA 18.2

- Chronic

leukemias




S

03.08

.2021

Tue

PH. 1.27

Antihypertensives

1 (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 2.1 Demonstrate

understanding of use of

various dosage forms

(oral, parenteral, Solid,

Liquid)I( DOAP

session) - parentral

PH 2.1

Demonstrat

e

understandi

ng of use of

various

dosage

forms (oral,

parenteral,

Solid,

Liquid)I(

DOAP

session) -

Oral

04.08

.2021

Wed

IM4.8 Discuss and

describe the

pathophysiology,

aetiology and

clinical

manifestations of

fever of unknown

origin (FUO)

including in a

normal host

neutropenic host,

nosocomial host,

host, host and a

host with HIV

disease

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY

SGD MI 4.3

,6.1Dengue

MICROBI

OLOGY

(PRACTIC

AL)

MI 2.7,

8.15HIV

and Dengue

PATH(S

GT) PA

18.2-

Other

MPDs,

MDS

05.08

.2021

Thur

CM(L)&(SDL)CM3.2 Describe concepts of safe and wholesome water, sanitary sources of water, water purification processes, water quality standards, concepts of water conservation and rainwater harvesting (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

FM 9.4,1.9 : INTEG

WITH PHARM & GM

Alcohol- II -

Lecture,SGD,DOAP

FM 9.4,1.9

: INTEG

WITH

PHARM &

GM

Alcohol- II

-

Lecture,SG

D,DOAP




06.08

.2021

Fri

MICROBIOLOG

Y(LECTURE) MI

1.1 Rickettesial

infections I

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

CM(SGT/INTG/TUTO)CM3.1 Describe the health hazards of air, water, noise, radiation and pollution (S)

07.08

.2021

Sat

IA(MICRO) IA

LU

NC

H

OBGY(L)OG 12.1


describe the etiology

and pathophysiology,

early detection,

investigations;

principles of

management of

hypertensive disorders

of pregnancy and

eclampsia,

complications of

eclampsia.

SU27.7

Describe

pathophysi

ology,

clinical

features,

investigatio

ns and

principles

of

manageme

nt of

Lymph

edema,

lymphangit

is and

Lymphoma

s 1

09.08

.2021

Mon

PATH(L) Vertical

Integration with

Surgery-PA 19.1,

19.4-

Lymphadenopathy

; Hodgkin

lymphoma

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SGT/DOAP)

PA 19.5- Hodgkin

lymphoma

PATH(SG

T) PA 19.4-

NHL I

10.08

.2021

Tue

PH. 1.27

Antihypertensives

2 (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 4.2 Demonstrate

effects of drugs on

blood pressure using

computer simulated

learning I (skill lab)

PH 2.1

Demonstrat

e

understandi

ng of use of

various

dosage

forms (oral,

parenteral,

Solid,




Liquid) (

DOAP

session) -

Liquid

11.08

.2021

Wed

IM8.1 Describe

and discuss the

epidemiology,

aetiology and the

prevalence of

primary and

secondary

hypertension.

IM8.2 Describe

and discuss the

pathophysiology

of hypertension.

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H


MI 1.1 PUO

MICROBI

OLOGY

(PRACTIC

AL)

MI 1.2Acid

fast

staining

PATH(S

GT) PA

19.4-

NHL II

12.08

.2021

Thur

CM(SGT/INTG/TUTO)CM3.4 Describe the concept of solid waste, human excreta and sewage disposal(L) CM(L)&SDL

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

FM 8.10 : INTEG

WITH PHARM & GM

Analytical Toxicology -

Lecture,SGD

FM 8.10 :

INTEG

WITH

PHARM &

GM

Analytical

Toxicology

-

Lecture,SG

D

13.08

.2021

Fri

MICROBIOLOG

Y(LECTURE) MI

1.1 Rickettesial

infections II

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

CM3.5 Describe the standards of housing and the effect of housing on health(L)CM(L)&SDLCM3.7 Describe the mode of action, application cycle of commonly used insecticides & rodenticides(L)

14.08

.2021

Sat

IA(PHARM) IA

LU

NC

H

OBGY(SGT/INTG/SL)

OG19.1 Describe and

discuss the physiology

of puerperium, its

complications,

diagnosis and

management;

counselling for

contraception,

SU27.7

Describe

pathophysi

ology,

clinical

features,

investigatio

ns and

principles




puerperal sterilization of

manageme

nt of

Lymph

edema,

lymphangit

is and

Lymphoma

s 2

16.08

.2021

Mon

PATH(L) PA

20.1- Plasma cell

myeloma

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(DOAP) PA

20.1- Plasma cell

myeloma

PATH(DO

AP) PA

19.6, 19.7-

Splenomeg

aly

17.08

.2021

Tue

PH. 1.28 Anti

anginal drugs (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH: 3.5 Prepare and

explain list of P drug to

given patient

PH 2.1

Demonstrat

e

understandi

ng of use of

various

dosage

forms IV (

DOAP

session)

Skill station

18.08

.2021

Wed

IM4.3 Discuss and

describe the

common causes,

pathophysiology

and

manifestations of

fever in various

regions in India

including

bacterial, parasitic

and viral causes

(e.g.Dengue,

Chikungunya,

Typhus

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY

SDL MI 3.6 Acid

peptic diseases

MICROBI

OLOGY

(PRACTIC

AL)

MI 1.2Acid

fast

staining

PATH(S

GT) PA

28.1,

28.2 to

28.4-

Normal

histolog

y of

Kidney

& Renal

failure




19.08

.2021

Thur

CM(L)&(SDL)CM5.1 Describe the common sources of various nutrients and special nutritional requirements according to age, sex, activity, physiological conditions(L) CM(L)&(SDL)CM5.3 Define and describe common nutrition related health disorders (including macro-PEM, Micro-iron, Zn, iodine, Vit. A), their control & MGMT (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

FM 9.3 : Metallic

irritants -

Lecture,SGD,DOAP.

Bedside clinic

FM 9.3 :

Metallic

irritants -

Lecture,SG

D,DOAP.

Bedside

clinic

20.08

.2021

Fri

MICROBIOLOG

Y (LECTURE)

MI 1.1 Dengue,

chikungunya,and

Zikavirus

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

CM(SGT/INTG/TUTO)CM5.2 Describe and demonstrate the correct method of performing a nutritional assessment of individuals, families and the community by using the appropriate method(SGD) CM(SGT/INTG/TUTO)CM5.5 Describe the methods of nutritional surveillance, principles of nutritional education and rehabilitation in the context of sociocultural factors (SGD)

21.08

.2021

Sat

IA(PATH) IA

LU

NC

H

OBGY OG7.1 Describe

and discuss the changes

in the genital tract,

cardiovascular system,

respiratory,

haematology, renal and

gastrointestinal system

in pregnancy

SU26.1

Outline the

role of

surgery in

the

manageme

nt of

coronary

heart

disease,

valvular

heart

diseases

and

congenital




heart

diseases

23.08

.2021

Mon

PATH(L) Vertical

Integration with

GM-PA 28.5-

Glomerular

diseases I

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SGT) PA 28.5-

Glomerular diseases II

PATH(SG

T) PA 28.6,

PA 28.7-

Glomerular

diseases III

24.08

.2021

Tue

PH. 1.29 Drugs

for heart failure

(L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 3.4 To recognize

and report ADR (Skill

Station)

PH 3. 6

Demonstrat

e how to

optimize

interaction

with

pharmaceut

ical

representati

ves to get

authentic

information

on drug

(Skill

Station)

25.08

.2021

Wed

IM10.1 Define,

describe and

differentiate

between acute and

chronic renal

Failure

IM10.2 Classify,

describe and

differentiate the

pathophysiologic

causes of

acute renal failure

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY

(SGD) M1.1 Other

hemorrhagic fever -

KFD, Ebola , Marburg

& Hanta

Practicals :

MI 6.2 MI

1.2 lab

diagnosis

of upper

respiratory

tract

infections

PATH(S

GT) PA

28.8, PA

28.9-

Tubuloi

nterstitia

l

diseases

I

26.08

.2021

Thur

CM(SGT/INTG/TUTO)CM7.1 Define Epidemiology and describe and enumerate the

CL

INI

CA

L

LU

NC

H

FM 9.6: INTEG WITH

PHARM & GM

Asphyxiants (CO,H2S)

-

Lecture,SGD,DOAP,Be

FM 9.6:

INTEG

WITH

PHARM &

GM




principles, concepts and uses(L)

PO

STI

NG

S

dside Asphyxiant

s (CO,H2S)

-

Lecture,SG

D,DOAP,B

edside

27.08

.2021

Fri

MICROBIOLOG

Y

(INTEGRATED)

MI 2.5, PA 10.1-

Malaria

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

CM(L)&(SDL)CM7.5 Enumerate, define, describe and discuss epidemiological study designs(L)

28.08

.2021

Sat

IA(MICRO) IA

LU

NC

H

OBGY(SGT/INTG/SL)

OG21.1 Describe and

discuss the temporary

and permanent methods

of contraception,

indications, technique

and complications;

selection of patients,

side effects and failure

rate including Ocs,

male contraception,

emergency

contraception and

IUCD

SU27.1

Describe

the

etiopathoge

nesis,

clinical

features,

investigatio

ns and

principles

of

treatment

of

occlusive

arterial

disease.

30.08

.2021

Mon

PATH(SGT) PA

28.8, PA 28.9-

Tubulointerstitial

diseases II

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SGT) PA 28.11-

Vascular diseases of

Kidney

PATH(SG

T) PA

28.12-

Cystic

diseases of

Kidney

31.08

.2021

Tue

PH. 1.30

Antiarrhythmic

drugs (L)

CL

INI

CA

L

LU

NC

H

PH 1.47: Animalarials

(SGT)

PH 4.2

Demonstrat

e effects of

drugs on

blood




PO

STI

NG

S

pressure

using

computer

simulated

learning II

(skill lab)

01.09

.2021

Wed

IM10.5 Describe

and discuss the

aetiology of CRF

IM10.6 Stage

Chronic Kidney

Disease

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY(SG

D) MI 1.1

Trypanosomiasis &

Schistosomiasis

Practicals :

MI 1.3

Stool

examinatio

n

peripheral

smear

examinatio

n

PATH(S

GT)

Vertical

Integrati

on with

Surgery-

PA

28.13-

Obstruct

ive

uropathy

02.09

.2021

Thur

CM(L)&(SDL)C

M7.6 Enumerate

and evaluate the

need of screening

tests(L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

FM 9.5 : Agricultural

poisons -

Lecture,SGD,DOAP,Be

dside

FM 10.1 :

Pharmaceut

ical

toxicology-

I -

Lecture,SG

D,DOAP,B

edside

3.09.

2021

Fri

MICROBIOLOG

Y (LECTURE)

MI

2.5Leishmaniasis

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H CM(L)&(SDL)CM7.6

Enumerate and evaluate

the need of screening

tests(SGT)

CM(L)&(S

DL)CM7.6

Enumerate

and

evaluate the

need of

screening

tests(SGT)

4.09.

2021

Sat

IA(PHARM) IA

LU

NC

H

OBGY(SGT/INTG/SL)

OG 10.2 enumerate the

indication and describe

appropriate use of

blood and blood

products,their

complication and

management

SU29.6

Describe

the clinical

features,

investigatio

ns and

principles

of

manageme

nt of renal




tumours

6.9.2

021

Mon

PATH(L) PA

28.14, PA 28.16-

Renal and

Urothelial tumors

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SGT) Vertical

Integration with

Surgery-PA 29.1-

Testicular tumors

PATH(SG

T) Vertical

Integration

with

Surgery-PA

29.2-

Carcinoma

Penis

7.9.2

021

Tue

PH1.24 Diuretics

& Antidiuretics

(L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

Seminar PH 1.26 &

1.27 Cardiovascular

Disorders

PH 5.1

Communic

ate with the

patient with

empathy

and ethics

on all

aspects of

drug use

(SGT)

8.9.2

021

Wed

IM10.7 Describe

and discuss the

pathophysiology

and clinical

findings of

uraemia

IM10.8 Classify,

describe and

discuss the

significance of

proteinuria in

CKD.

IM10.9 Describe

and discuss the

pathophysiology

of anemia and

hyperparathyroidis

m in CKD

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY

SGD MI 2.5

Lymphatic filariasis

MICROBI

OLOGY(Pr

acticals)

MI 6.2 MI

6.3 MI 1.2

Lab

diagnosis

of lower

respiratory

tract

infections

,Acid fast

staining

PATH(S

GT)Vert

ical

Integrati

on with

Surgery-

PA 29.3-

BPH




9.9.2

021

Thur

CM(SGT/INTG/TU

TO)CM1.3

Describe the characteristics of

agent, host and

environmental

factors in health and disease and the

multi factorial

etiology of disease(L)

CM(L)&SDLCM1.

4 Describe and

discuss the natural history of

disease(L)

CM(SGT/INTG/TUTO)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

FM 10.1 :

Pharmaceutical

toxicology -II -

Lecture,SGD,DOAP,Be

dside

FM 10.1 :

Pharmaceut

ical

toxicology

-II -

Lecture,SG

D,DOAP,B

edside

10.9.

2021

Fri

MICROBIOLOG

Y (LECTURE)

MI 2.5 Lymphatic

filariasis

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

CM(SGT/INTG/TUTO)CM1.5 Describe the application of interventions at various levels of prevention(L)

11

.9.20

21

Sat

IA(PATH) IA

LU

NC

H

OBGY(L) OG 10.1

define ,classify and

describe the

etiology,pathogenesis,cl

inical

features,ultrasonograph

y,differential diagnosis

and management of

antepartum

haemorrhage in

pregnancy

SU27.7

Describe

pathophysi

ology,

clinical

features,

investigatio

ns and

principles

of

manageme

nt of

Lymph

edema,

lymphangit

is and

Lymphoma

s (3)




13.9.

2021

Mon

PATH(L) Vertical

Integration with

Surgery-PA 29.4-

Carcinoma

Prostate

LU

NC

H

PATH(DOAP) PA

28.14-Renal tumors

PATH(DO

AP) PA

23.1-

Urinary

sediments

14.9.

2021

Tue

PH 1.37

Introduction to

Hormone &

Anterior Pitituary

Hormones (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.36 Drugs

affecting calcium

metabolism (SGT)

PH 5.2

Communic

ate with the

patient

regarding

optimal use

of a) drug

therapy, b)

devices and

c) storage

of

medicines

(SGT)

15.9.

2021

Wed

IM13.1 Describe

the clinical

epidemiology and

inherited &

modifiable risk

factors for

common

malignancies in

India

IM13.2 Describe

the genetic basis

of selected cancers

IM13.3 Describe

the relationship

between infection

and cancers

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY

(SGD) MI 1.1

Systemic mycosis &

Candidiasis

MICROBI

OLOGY

Practicals

MI 14.3 lab

diagnosis

of fungal

and viral

skin

infections

PATH(S

eminar)

PA 28.5-

Medical

Renal

disease

16.9.

2021

Thur

CM(L)&(SDL)CM8.1 Describe and discuss the epidemiological and control measures including the use of essential laboratory tests at the primary care level for communicable disease chicken

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

FM 10.1 :

Pharmaceutical

toxicology - III -

Lecture,SGD,DOAP,Be

dside

FM 10.1 :

Pharmaceut

ical

toxicology

- III -

Lecture,SG

D,DOAP,B

edside




pox, measles, mumps, rubella (S)

17.9.

2021

Fri

MICROBIOLOG

Y(LECTURE)

MI 3.3 Enteric

(Typhoid) ever

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

CM(L)&(SDL)CM8.1 Describe and discuss the epidemiological and control measures including the use of essential laboratory tests at the primary care level for communicable disease - Tuberculosis- (IT)

18

.9.20

21

Sat

IA(MICRO) IA

LU

NC

H

OBGY(SGT/INTG/SL)

OG 22.2 Describe and

discuss the etiology

(with special emphasis

on

Candida, T. vaginalis,

bacterial vaginosis),

characteristics, clinical

diagnosis,

investigations, genital

hygiene, management

of common

causes and the

syndromic management

SU28.10

Describe

the applied

anatomy of

liver.

Describe

the clinical

features,

Investigatio

ns and

principles

of

manageme

nt of liver

abscess,

hydatid

disease,

injuries and

tumors of

the liver

20.9.

2021

Mon

PATH(L) Vertical

Integration with

GM-PA 25.4-

Cirrhosis

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SGT) PA 25.4-

Alcoholic liver disease

PATH(DO

AP) PA

25.4-

Alcoholic

liver

disease &

Cirrhosis




21.9.

2021

Tue

PH 1.34

Antiemetics &

Prokinetics Int

GM (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.41 uterine

relaxants and

Stimulants (SGT)

PH 5. 3

Motivate

patients

with

chronic

diseases to

adhere to

the

prescribed

manageme

nt by the

health care

provider

(SGT)

22.9.

2021

Wed

IM5.2 Describe

and discuss the

aetiology and

pathophysiology

of liver

Injury.

IM5.3 Describe

and discuss the

pathologic

changes in various

forms of

liver disease

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY

(SGD) MI 3.1

Shigellosis

MICROBI

OLOGY

practicals

MI 3.1 MI

3.2 MI 1.2

Lab

diagnosis

of dysentry

PATH(S

GT) PA

25.4-

Biliary

Cirrhosi

s

23.9.

2021

Thur

CM(L)&(SDL)CM8.1 Describe and discuss the epidemiological and control measures including the use of essential laboratory tests at the primary care level for communicable disease- ARI (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

FM 10.1 :

Pharmaceutical

toxicology - IV -

Lecture,SGD,DOAP,Be

dside

FM 10.1 :

Pharmaceut

ical

toxicology

- IV -

Lecture,SG

D,DOAP,B

edside

24.9.

2021

Fri

MICROBIOLOG

Y(LECTURE)

MI 3.1Cholera and

halophilic Vibrio

infections

CL

INI

CA

L

PO

STI

NG

LU

NC

H

CM(L)&(SDL)CM8.1 Describe and

discuss the epidemiological and control measures including the use of essential

laboratory tests at the primary care level

for communicable disease Influenza, Diphtheria, Whooping cough,

Meningococcal Meningitis, SARS,

COVID (S)




S

25

.9.20

21

Sat

IA (OBGY) IA

LU

NC

H

OBGY(SGT/INTG/SL)

OG 9.5 Describe the

etiopathology, impact

on maternal and fetal

health and

principles of

management of

hyperemesis

gravidarum

SU28.12

Describe

the applied

anatomy of

biliary

system.

Describe

the

clinical

features,

investigatio

ns and

principles

of

manageme

nt of

diseases of

biliary

system

27.9.

2021

Mon

PATH(Vertical

Integration with

GM) PA 25.2-

Hepatic failure

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SGT) Vertical

Integration with GM &

Surgery PA 25.5- Portal

Hypertension

PATH(SG

T)-PA

25.5- Portal

Hypertensi

on II

28.9.

2021

Tue

PH 1.34 Drugs for

constipation (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.34 Anti-

diarrhoeals (SGT)

PH 5.4

Explain to

the patient

the

relationship

between

cost of

treatment

and patient

compliance

(SGT)




29.9.

2021

Wed

IM5.6 Describe

and discuss the

pathophysiology,

clinical evolution

and

complications of

cirrhosis and

portal

hypertension

including ascites,

spontaneous

bacterial

peritonitis,

hepatorenal

syndrome and

hepatic

encephalopathy.

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY

(SGD) NTS &

Diarrheogenic E.coli II

MICROBI

OLOGY

practicals

MI 3.1 MI

3.2 MI 1.2

Lab

diagnosis

of diarrhea

PATH(S

GT) PA

25.4-

Cirrhosi

s

complic

ations &

HCC

30.9.

2021

Thur

CM(L)&(SDL)CM8

.1 Describe and discuss the

epidemiological and

control measures including the use of

essential laboratory

tests at the primary care level for

communicable

disease

Poliomyelitis (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

FM 12.1 : Sociomedical

Toxicology - I -

Lecture,SGD, Autopsy

FM 12.1 :

Sociomedic

al

Toxicology

- II -

Lecture,SG

D, Autopsy

01.10

.2021

Fri

MICROBIOLOG

Y(LECTURE)

MI 3.1Intestinal

amoebiasis

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H


discuss the epidemiological and control

measures including the use of essential

laboratory tests at the primary care level for communicable disease typhoid,,

Amoebiasis, Ascariasis, Hookworm

infection, Dracunculiasis (S)

02

.10.2

021

Sat

GANDHI JAYANTI HOLIDAY

04.10

.2021

Mon

PATH(L) Vertical

Integration with

GM-PA 24.2-

H.Pylori and

CL

INI

CA

LU

NC

H

PATH(SGT) PA 24.2-

H.Pylori gastritis

PATH(DO

AP) PA

24.3-

Peptic ulcer




Peptic ulcer

disease

L

PO

STI

NG

S

05.10

.2021

Tue

PH 1.34 Drugs for

peptic Ulcer &

GERD (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

Seminar PH 1.36

Antidaibetic Drugs

PH

5.5Demons

trate an

understandi

ng of the

caution in

prescribing

drugs likely

to produce

dependence

and

recommend

the line of

manageme

nt (SGT)

06.10

.2021

Wed

IM15.1

Enumerate,

describe and

discuss the

aetiology of upper

and lower

GI bleeding

IM15.2

Enumerate,

describe and

discuss the

evaluation and

steps involved

in stabilizing a

patient who

presents with

acute volume loss

and GI bleed.

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY(SD

G) MI

3.6 & MI 3.1

Helicobacter ,

Campylobacter &

yersinia

MICROBI

OLOGY

practicals

MI 3.1 MI

3.2 MI 2.5

MI 2.4 MI

1.2 Lab

diagnosis

of intestinal

helminthic

infections

PATH(S

GT) PA

24.7-

Intestina

l polyps

07.10

.2021

Thur

CM(L)&(SDL)CM8

.1 Describe and

discuss the

epidemiological and control measures

including the use of

essential laboratory

CL

INI

CA

L

PO

STI

LU

NC

H

FM 9.1 : Corrosive

poisons - Lecture

FM 9.2, 9.3

: Inorganic

irritants -

Lecture




tests at the primary

care level for

communicable disease

ADD,Cholera (L)

NG

S

08.10

.2021

Fri

MICROBIOLOG

Y(SGD)

MI 3.5 Food

Poisoning -

Bacillus,

clostridium

botulinum

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H


discuss the epidemiological a

Investigation of food poison outbreak

(SGD)

09

.10.2

021

Sat

IA (GENERAL

SURGERY) IA

LU

NC

H

OBGY(L) OG12.6

Describe the clinical

features, detection,

effect of pregnancy on

the

disease and impact of

the disease on

pregnancy

complications and

management of liver

disease in pregnancy

SU28.8

Describe

and discuss

the

aetiology,

the clinical

features,

investigatio

ns and

principles

of

manageme

nt of

congenital

hypertrophi

c pyloric

stenosis,

Peptic ulcer

disease,

Carcinoma

stomach

11.10

.2021

Mon

PATH(L)Vertical

Integration with

Surgery PA 24.4-

Carcinoma

Stomach

CL

INI

CA

L

PO

STI

NG

LU

NC

H

PATH(SGT) Vertical

Integration with

Surgery-PA 24.7-

Inflammatory Bowel

disease

PATH(DO

AP) PA

24.4-

Carcinoma

Stomach




S

12.10

.2021

Tue

PH 1.38

Corticosteroids

(L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.34 Drugs for IBS

& Pancreatic Disease

(SGT)

PH 5.6

Demonstrat

e ability to

educate

public &

patients

about

various

aspects of

drug use

including

drug

dependence

and OTC

drugs

(SGT)

13.10

.2021

Wed

IM16.1 Describe

and discuss the

aetiology of acute

and chronic

diarrhea

including

infectious and non

infectious causes

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY(SG

D) MI 3.1 Giardiasis,

Coccidian &

Microspora

MICROBI

OLOGY

practicals

MI 3.7 M.I

3.8 Lab

diagnosis

of hepatic

infections

PATH(S

GT/DO

AP)

Vertical

Integrati

on with

Surgery-

PA 24.7-

Carcino

ma

colon

14.10

.2021

Thur

Ayuda puja holiday

15.10

.2021

Fri

MICROBIOLOG

Y(LECTURE)

MI 3.1Intestinal

nematodes

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H


discuss the epidemiological and control measures including the use of essential

laboratory tests at the primary care level

for communicable disease (other vector borne diseases (S)




16

.10.2

021

Sat

IA (GENERAL

MEDICINE) IA

LU

NC

H

OBGY(SGT/INTG/SL)

OG12.7 Describe and

discuss screening, risk

factors, management of

mother and newborn

with HIV

SU28.14

Describe

the clinical

features,

investigatio

ns and

principles

of

manageme

nt of

disorders of

small and

large

intestine

including

neonatal

obstruction

and Short

gut

syndrome

18.10

.2021

Mon

PATH(L) Vertical

Integration with

GM-PA 25.3-

Viral hepatitis

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SGT) PA 25.3-

Toxic hepatitis

PATH(DO

AP) PA

25.6-

Interpretati

on of Viral

hepatitis

serology

and LFT

19.10

.2021

Tue

PH. 1.37

Estrogens (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 5.7 Demonstrate an

understanding of the

legal and ethical

aspects of prescribing

drugs (SGT)

PH 1.31

Drugs used

in

Dyslipdemi

as (SGT)

20.10

.2021

Wed

MICROBIOLOG

Y(LECTURE)

MI 3.7Agents of

Viral Hepatitis

CL

INI

CA

L

PO

STI

LU

NC

H

MICROBIOLOGY(SG

D)

MI 3.1 Intestinal

cestodes

MICROBI

OLOGY

Practicals

M! 2.7 M!

.12 MI 8.14

1.Lab

diagnosis




NG

S

of HIV

infection

2.Confident

iality

pertaining

to patient' s

identity in

lab results

21.10

.2021

Thur

Pandemic module

2.5 Therapeutic

strategies

including new

drug

development.Phar

macology (1/3)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

IM5.4 Describe and

discuss the

epidemiology,

microbiology,

immunology

and clinical evolution

of infective (viral)

hepatitis

PATH

(SGT)-

Cholecystit

is,

Cholangioc

arcinoma

22.10

.2021

Fri

PATH(L) PA

25.3- Liver

abscess

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.60

Pharmacogenmics &

Pharmacoeconomics

(SDL)

PATH(SD

L) PA 25.4-

Cholelithia

sis

23

.10.2

021

Sat

IA(PHARM) IA

LU

NC

H

OBG-( L) OG 27.1


etiology,pathology,clini

cal features,differential

diagnosis,investigation,

management and long

term implication of

sexually transmitted

infection

SU18.1

Describe

the

pathogenesi

s, clinical

features

and

manageme

nt of

various

cutaneous

and

subcutaneo

us

infections.

25.10

.2021

Mon

PATH(L) Vertical

Integration with

Ortho) PA 33.1-

Osteomyelitis

CL

INI

CA

LU

NC

H

PATH(SGT) Vertical

Integration with Ortho-

PA 33.4- Paget disease

of Bone

PATH(SG

T) Vertical

Integration

with GM-




L

PO

STI

NG

S

PA 33.5-

Rheumatoi

d arthritis,

OA,

Seronegativ

e arthritis

26.10

.2021

Tue

PH 1.16 Drug

therapy for RA

and Gout (INT)

medicine (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

Seminar PH 1.34 GIT I

Seminar

PH 1.34

GIT II

27.10

.2021

Wed

MICROBIOLOG

Y (LECTURE)

MI 4.1, 4.2, 4.3

Infective

syndromes of skin,

soft tissue,

musculoskeletal

systems (in brief)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY(SG

D) MI 1.1

Echinococcus(hydatid

cyst), Amoebic liver

abscess Faciola

hepatica, Clonorchis

sinensis

Microbiolo

gy MI

4.3Practical

s lagb

diagnosis

of Bacterial

skin

infection(B

acterial

,Burns

wound,lepr

osy)

28.10

.2021

Thur

Pandemic module

2.5 Therapeutic

strategies

including new

drug

development.Phar

macology (2/3)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

IM7.5 Describe and

discriminate acute,

subacute and chronic

causes of joint pain.

IM7.6 Discriminate,

describe and discuss

arthralgia from arthritis

and

mechanical from

inflammatory causes of

joint pain.

PATH(L)

PA 33.2-

Bone

tumors I

29.10

.2021

Fri

PATH(L) PA

33.2-Bone tumors

II

CL

INI

CA

L

PO

STI

LU

NC

H

PH 1.64 Phases of

clinical trial (SDL)

PATH(SD

L) PA 32.6-

Pancreatitis




NG

S

30

.10.2

021

Sat

IA(PATH) IA

LU

NC

H

OBG OG 31.1

Describe and discuss

the etiology,

classification, clinical

features,diagnosis,

investigations,

principles of

management and

preventive

aspects of prolapse of

uterus

SU18.2

Classify

skin tumors

Differentiat

e different

skin tumors

and discuss

their

manageme

nt.

01.11

.2021

Mon

PATH(L) PA

33.2-Bone tumors

III

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SGT) PA 34.1

to 34.3- SCC, BCC,

Malignant melanoma

PATH(DO

AP) PA

34.4- SCC,

BCC,

Malignant

melanoma

02.11

.2021

Tue

PH 1.37:

Antiestrogens (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

Seminar PH 1.18 GA

Seminar

PH 1.19

Sedative

Hypnotics

03.11

.2021

Wed

Diwali Holiday

04.11

.2021

Thur

05.11

.2021

Fri

06

.11.2

021

Sat

IA(MICRO) IA

LU

NC

H

OBGY(L) OG 27.4


the etiology, pathology,

clinical features,

SU18.2

Classify

skin tumors

Differentiat




differential diagnosis,

investigations,

management and long

term implications of

Pelvic Inflammatory

Disease

e different

skin tumors

and discuss

their

manageme

nt.

08.11

.2021

Mon

PATH(L) PA

33.3- Common

Soft tissue tumors

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SGT) Vertical

integration with OG)

PA 30.1- Carcinoma

cervix

PATH(DO

AP)PA

30.1-

Carcinoma

cervix II

09.11

.2021

Tue

PH 1.37

Progestins & Anti

progestins (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.39 :

contraceptives (SGT) I

PH 1.39 :

contracepti

ves (SGT)

II

10.11

.2021

Wed

MICROBIOLOG

Y(LECTURE)

MI 4.3

Staphylococcal

infections

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY

SGD MI 4.1, 4.3

Anaerobic infections

MICROBI

OLOGY

(PRACTIC

AL)

MI 4.1,

4.3,Staphyl

ococcal,

Streptococc

al

infections

and

Anaerobic

11.11

.2021

Thur

Pandemic module

2.5 Therapeutic

strategies

including new

drug

development.Phar

macology (3/3)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

IM3.1 Define, discuss,

describe and distinguish

community acquired

pneumonia, nosocomial

pneumonia and

aspiration pneumonia.

PATH(L)V

ertical

integration

with OG)

PA 30.2-

Carcinoma

endometriu

m




12.11

.2021

Fri

PATH(L) Vertical

Integration with

OG-PA 30.9-

Endometrial

hyperplasia

LU

NC

H

PH 1.44 & PH 1.45

Antitubercular drugs

(SDL)

PATH(SD

L) PA 11.1-

Diagnostic

techniques

for Genetic

disorders

13

.11.2

021

Sat

IA(PHARM) IA

LU

NC

H

OG 33.1 Classify,


etiology, pathology,

clinical features,

differential diagnosis,

investigations and

staging of cervical

cancer.

SU22.2

Describe

the

etiopathoge

nesis of

thyroidal

swellings

15.11

.2021

Mon

PATH(L) Vertical

Integration with

OG-PA 30.7, PA

30.8-

Endometriosis and

Adenomyosis

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SGT) Vertical

Integration with OG-

PA 30.3-Leiomyoma &

Leiomyosarcoma

PATH(DO

AP)-PA

30.3, PA

30.2, 30.8-

Leiomyom

a, Ca

Endometriu

m,

Adenomyo

sis

16.11

.2021

Tue

PH 1.36 Thyroid

Disorders &

Management (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

Seminar PH 1.48 Beta

lactum antibiotics I

Seminar

PH 1.48

Beta lactum

antibiotics

II

17.11

.2021

Wed

MICROBIOLOG

Y(SDL)

MI 4.1

Streptococcal

infections

pertaining to SSTI

Anthrax

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY

(SGD) MI

4.3,Infection due to

Non

fermenters(Pseudomon

as,Acinetobacter,Stenot

rophomonas,Burkholde

ria including

Melioidosis)

Microbiolo

gy

Practicals

MI 4.2 MI

1.2 lab

diagnosis

of

musculoske

letal

infections




18.11

.2021

Thur

Pandemic module

2.5 Therapeutic

strategies

including new

drug

development.Gene

ral Medicine (1/3)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

IM6.1 Describe and

discuss the symptoms

and signs of acute HIV

Seroconversion.

IM6.2 Define and

classify HIV AIDS

based on the CDC

criteria.

PATH(L)

Vertical

Integration

with OG-

PA 30.4-

Ovarian

tumors I

19.11

.2021

Fri

PATH(L) PA

30.4- Ovarian

tumors II

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.48 Management

of HIV (SDL)

PATH(SD

L) PA 4.3-

Sarcoidosis

20.11

.2021

Sat

IA(PATH)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

IA

22.11

.2021

Mon

PATH(L) Vertical

Integration with

OG-PA 30.5-

Gestational

trophoblastic

diseases

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(DOAP) PA

30.4- Ovarian tumors I

PATH(DO

AP) PA

30.4-

Ovarian

tumors II

23.11

.2021

Tue

PH 1.36: Insulin

& Analogues -

INT GM (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

Seminar PH 1.48 Anti

cancer I

Seminar

PH 1.48

Anti cancer

II




24.11

.2021

Wed

MICROBIOLOG

Y(LECTURE)

MI 4.3Viral

exanthems -

Measles, rubella,

parvovirus

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY

(SGL) MI 4.3 Tissue

nematode of skin & soft

tissue: Onchocerca, Loa

Loa, Monsonella ,

Drancunculus,

Trichinella,

Cysticercosis, Larva

migrans & other

parasitic

Microbiolo

gy

practicals

MI 15.3

Lab

diagnosis

of

Encephaliti

s

25.11

.2021

Thur

Pandemic module

2.5 Therapeutic

strategies

including new

drug

development.Gene

ral Medicine (2/3)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

IM12.1 Describe the

epidemiology and

pathogenesis of

hypothyroidism and

hyperthyroidism

influence iodine

including the of

deficiency and

autoimmunity in the

pathogenesis of thyroid

disease

PATH(L)V

ertical

Integration

with

Surgery PA

32.1-

Goitrous

Thyroid

swelling

evaluation

26.11

.2021

Fri

PATH(L) PA

32.2, PA 32.3-

Graves disease,

Thyroiditis,

Thyroid tumors

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.47 Management

of malaria (SDL)

PATH(SD

L) PA 26.5-

Interstitial

Lung

diseases

27.11

.2021

Sat

IA (MICRO) IA

LU

NC

H

OBGY OG 29.1


the etiology; pathology;

clinical features;

differential diagnosis;

investigations;

principles of

management,

complications of fibroid

uterus

SU22.6

Describe

and discuss

the clinical

features of

hypo - and

hyperparath

yroidism

and the

principles

of their

manageme

nt




29.11

.2021

Mon

PATH(L) Vertical

Integration with

GM-PA 32.7,

32.8-Adrenal

insufficiency and

Cushing syndrome

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SGT) PA 32.5-

Hyperparathyroidism

PATH(SG

T) Vertical

Integration

with

Surgery-PA

32.6, 32.9-

Adrenal

neoplasms

&

Pancreatic

cancer

30.11

.2021

Tue

PH 1. 36 Oral

Hypoglycemic

agents (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PH 1.6 ADR reporting

systems (P)

PH 1.6

Pharmacovi

gilliance

(SGT)

01.12

.2021

Wed

MICROBIOLOG

Y (LECTURE)

MI 4.3Superficial

fungal infections

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY

SGD MI

4.3, 8.15 Subcutaneous

fungal infections

MICROBI

OLOGY

(PRACTIC

AL)

MI 4.3,

8.15SSTI

due to

Superficial

and

Subcutaneo

us fungal

infections

02.12

.2021

Thur

Pandemic module

2.5 Therapeutic

strategies

including new

drug

development.Gene

ral Medicine (3/3)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

IM11.1 Define and

classify diabetes

IM11.3 Describe and

discuss the

epidemiology and

pathogenesis and risk

factors economic

impact and clinical

evolution of type 2

diabetes

PATH(L)V

ertical

Integration

with GM

PA 32.4-

Diabetes

mellitus I

03.12

.2021

Fri

PATH(L) PA

32.4-Diabetes

mellitus II

CL

INI

LU

NC

H

PATH(SDL) PA 5.1,

PA 7.2- Angiogenesis

PH 1.4

Membrane

Transporter




CA

L

PO

STI

NG

S

s (SDL)

04.12

.2021

Sat

IA (PHARM) IA

LU

NC

H

OBGY OG 12.3


describe the etiology,

pathophysiology,diagno

sis, investigations,

criteria, adverse effects

on the mother and

foetus and the

management during

pregnancy and labor,

and

complications of

diabetes in pregnancy

SU20.1

Describe

etiopathoge

nesis of

oral cancer

symptoms

and signs

of

oropharyng

eal cancer.

06.12

.2021

Mon

PATH(L) Vertical

Integration with

GM-PA 35.1-

Meningitis

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SGT) PA 24.1-

Oral cancers

PATH(SG

T) Vertical

Integration

with

Ophthal-

PA 36.1-

Retinoblast

oma

07.12

.2021

Tue

PH 1.57 & 1.58

Drugs used in

Skin & Occular

Disorders (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

Seminar PH 1.19

Antiepileptics I

Seminar

PH 1.19

Antiepilepti

cs II

08.12

.2021

Wed

MICROBIOLOG

Y (LECTURE)

MI 5.1Infective

syndromes of

CNS (in brief)

CL

INI

CA

L

PO

STI

NG

LU

NC

H

MICROBIOLOGY(SG

D) MI 1.1.infective

syndromes of

eyes,Nose,throat

Microbiolo

gy

practicals

MI 5.3 lab

diagnosis

of

meningitis




S

09.12

.2021

Thur

Pandemic module

.Vaccination

strategies

including vaccine

development &

implementation(Bi

ochemistry)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

IM18.1 Describe the

functional and the

vascular

anatomy of the brain

IM18.2 Classify

cerebrovascular

accidents and describe

the aetiology,

predisposing genetic

and risk factors

pathogenesis of

hemorrhagic

and non hemorrhagic

stroke

PATH(L)

PA 35.2-

CNS

Tumors I

10.12

.2021

Fri

PATH(L) PA

35.2- CNS

Tumors II

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SDL) PA 5.1-

Stem cells

PH 1.23

Drugs of

abuse

(SDL)

11.12

.2021

Sat

IA (PATH) IA

LU

NC

H

OBGY OG 30.1


the etiopathogenesis;

clinical

features;differential

diagnosis;

investigations;

management,

complications of

PCOS

SU26.4

Describe

the

etiology,

pathogenesi

s, clinical

features of

tumors of

lung and

the

principles

of

manageme

nt

13.12

.2021

Mon

PATH(Integration

with Micro &

GM) PA 19.2, PA

24.5, PA 26.4-

CL

INI

CA

LU

NC

H

PATH(SGT)

Integration with

GM&Micro-PA 26.1,

PA 26.2- Pneumonia

PATH(DO

AP) PA

19.3-

Tuberculou




Tuberculosis L

PO

STI

NG

S

and Lung abscess s

lymphadeni

tis

14.12

.2021

Tue

PH 1.44 & PH

1.45

Antitubercular

drugs (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

seminar PH 1.19

Antiparkinsonism

seminar PH

1.19 CNS

stimulant

15.12

.2021

Wed

MICROBIOLOG

Y (LECTURE)

MI 6.1Viral

URTI-1: Major

Etiological agent

of upper & lower

respiratory tract

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY

(SDL) MI 7.2Agents of

genital ulcers

Microbiolo

gy

practicals

MI 7. 3 lab

diagnosis

of

genitourina

ry and

sexually

trasmitted

infections

16.12

.2021

Thur

Pandemic module

.Vaccination

strategies

including vaccine

development &

implementation(Bi

ochemistry)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

IM3.3 Discuss and

describe the

pathogenesis,

presentation, natural

history and

complications of

pneumonia.

PATH(L)

Vertical

Integration

with GM-

PA 26.3-

Obstructive

Airway

disease I

17.12

.2021

Fri

PATH(L) PA

26.3-Obstructive

Airway disease II

& Bronchiectasis

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SDL) PA 7.2-

Growth factors

PH 1.28

Manageme

nt of

myocardial

infraction

(SDL)




18.12

.2021

Sat

IA (MICRO) IA

LU

NC

H

OBGY OG 27.2


the etiology, pathology,

clinical

features,differential

diagnosis,

investigations,

management and long

term implications of

genital tuberculosis

SU26.3

Describe

the clinical

features of

mediastinal

diseases

and the

principles

of

manageme

nt

20.12

.2021

Mon

PATH(L) PA

28.10-

Pyelonephritis

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SGT) PA 30.6-

Cervicitis

PATH(SG

T) PA 29.5-

Prostatitis

21.12

.2021

Tue

PH 1.32:

Pharmacotherpy

Of BA & COPD

(L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

seminar PH 1.13

Adrenergics I

seminar PH

1.13

Adrenergic

s II

22.12

.2021

Wed

MICROBIOLOG

Y (LECTURE)

MI 8.5, MI

8.6Hospital

acquired

infections

(surveillance and

prevention)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY

(LECTURE) MI

7.3Normal commensals

of genitourinary tract

Urinary tract infection

Microbiolo

gy

practicals

MI 7.1 MI

7.2 lab

diagnosis

of Urinary

tract

infections

23.12

.2021

Thur

Pandemic module

.Vaccination

strategies

including vaccine

development &

implementation(Bi

ochemistry)

CL

INI

CA

L

PO

STI

LU

NC

H

IM4.7 Discuss and

describe the

pathophysiology and

manifestations of the

sepsis syndrome

PATH(L)

PA 26.5-

Pneumocon

iosis




NG

S

24.12

.2021

Fri

PATH(L) PA

26.6, 26.7-Tumors

of Lumg, Pleura

and Mesothelioma

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SDL) PA 22.5-

Transfusion

Transmitted Infections

PH 1.54

Vaccines

and its uses

(SDL)

25.12

.2021

Sat

CHRISTMAS

HOLIDAY

27.12

.2021

Mon

PATH(L) Vertical

Integration with

Surgery-PA 31.2-

Carcinoma Breast

I

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SGT) PA 31.2-

Carcinoma Breast II

PATH(DO

AP) PA

31.3-

Carcinoma

Breast

28.12

.2021

Tue

PH 1.33 Drugs for

cough (L)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

seminar PH 1.13

Antiadnergics I

seminar PH

1.13

Antiadnergi

cs II

Pandemi

c

module

.Vaccina

tion

strategie

s

includin

g

vaccine

develop

ment &

impleme

ntation(

Commu

nity

Medicin

e) 3:30-

4:30 pm




I hour

29.12

.2021

Wed

MICOBIOLOGY(

SGD)

MI 8.4 Emerging

& Reemerging

infections

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

MICROBIOLOGY

(LECTURE) MI1.1,8.1

Vector borne and

Zoonotic infetions

Microbiolo

gy

practicals

MI 7.3 lab

diagnosis

of sexually

transmitted

infections

Pandemi

c

module

.Vaccina

tion

strategie

s

includin

g

vaccine

develop

ment &

impleme

ntation(

Commu

nity

Medicin

e) 3:30-

4:30 pm

I hour

30.12

.2021

Thur

Pandemic module

.Vaccination

strategies

including vaccine

development &

implementation(Bi

ochemistry/CM)

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

IIM9.17 Describe the

indications for blood

transfusion and the

appropriate

use of blood

components

PATH(L)V

Integration

with

Surgery PA

31.1, PA

31.4-

Benign

Breast

diseases

including

Gynaecoma

stia

31.12

.2021

Fri

PATH(L) PA

31.2- Carcinoma

Breast -MCQs

CL

INI

CA

L

PO

STI

NG

S

LU

NC

H

PATH(SDL) PA 22.7-

Autologous transfusion

PH 1.49

Cancer

Chemother

apy (SDL)




Documents

KARPAGA VINAYAGA INSTITUTE OF MEDICAL SCIENCES AND